Skip to content. | Skip to navigation

European Coalition on Homeopathic & Anthroposophic Medicinal Products


Chronic disease

In 2010, the Council of Ministers invited EU Member States and the European Commission to identify ways to optimise the response to chronic diseases and the cooperation between EU countries. This led to the launch of a Joint Action (i.e. jointly financed and executed by the Commission and interested Member States) on Chronic Disease – JA CHRODIS -  was launched in 2014, addressing the challenge of the increased burden that chronic conditions and diseases place on health systems and individuals in Europe, with a specific focus on multi morbidity (co-existence of two or more chronic diseases in one person). The main objectives are to map innovative actions in social media, behavioural science and new technologies, examine barriers to uptake for prevention, targeted screening of risk groups, and treatment of major chronic diseases (using diabetes as an example) and look in more detail at how to address multi morbidity.

The Joint Action consists of six core work packages:

  • Chronic health: Platform for knowledge management and exchange
  • Good practices to address health promotion and prevention of chronic conditions
  • Development of common guidance and methodologies for care pathways for multi-morbid patients
  • Diabetes: a case study on barriers to prevention, screening and treatment of diabetes and improvement of cooperation among MS to act on diabetes
  • Sustainability and future developments
  • Disease management.

Why is this relevant for ECHAMP?

Cochrane reviews show that CAM therapies, including homeopathy and anthroposophic medicine, may have benefits for cancer patients on measures of Quality of Life, psychological wellbeing, adverse effects of cancer treatments, and may impact on survival. Homeopathic and anthroposophic medicinal products, with their holistic therapeutic approaches, demonstrate special success in the prevention and management of chronic disease; they have a safe and affordable track record and increased patient interest can play a major role.

Related content

Last updated on 14 Jun 2016